Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemcitabine Plus S-1 as the First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer

NCT03869294 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT03869294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03869294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemcitabine Plus S-1 as the First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer
Lead sponsor
Zhejiang University
Phase
Observational
Overall status
Completed
Start date
January 1, 2014
Completion date
December 31, 2017
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic toxicity, chemotherapy effect, pancreatic cancer